These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33287795)

  • 21. An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
    Abrams EJ; Jao J; Madlala HP; Zerbe A; Catalano P; Gerschenson M; Goedecke JH; Gomba Y; Josefson J; Kurland IJ; Legbedze J; McComsey GA; Matyesini S; Mukonda E; Robinson D; Myer L
    PLoS One; 2024; 19(8):e0307296. PubMed ID: 39159183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
    Wilson HI; Mapesi H
    Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
    [No Abstract]   [Full Text] [Related]  

  • 23. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda.
    Mbabazi L; Nabaggala MS; Kiwanuka S; Kiguli J; Laker E; Kiconco A; Okoboi S; Lamorde M; Castelnuovo B
    BMC Womens Health; 2022 Jun; 22(1):262. PubMed ID: 35761248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa.
    Migisha R; Chen G; Muyindike WR; Aung TN; Nanfuka V; Komukama N; Chandiwana N; Shazi G; Tien D; Moosa MS; Gupta RK; Pillay D; Marconi VC; Hedt-Gauthier B; Venter WDF; Siedner MJ; McCluskey SM; Manne-Goehler J
    AIDS; 2024 Jul; 38(9):1314-1322. PubMed ID: 38507584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study.
    Hurbans N; Naidoo P
    BMC Infect Dis; 2024 Mar; 24(1):343. PubMed ID: 38515041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
    Nabitaka VM; Nawaggi P; Campbell J; Conroy J; Harwell J; Magambo K; Middlecote C; Caldwell B; Katureebe C; Namuwenge N; Atugonza R; Musoke A; Musinguzi J
    PLoS One; 2020; 15(5):e0232419. PubMed ID: 32459822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®.
    Saint-Lary L; Lacroix I; Leroy V; Sommet A
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1247. PubMed ID: 39086081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gestational weight gain and adverse birth outcomes in South African women with HIV on antiretroviral therapy and without HIV: a prospective cohort study.
    Madlala HP; Myer L; Jao J; Geffen H; Matjila M; Fisher A; Meyer D; Werner EF; Petro G; Cu-Uvin S; McGarvey ST; Bengtson AM
    J Int AIDS Soc; 2024 Jun; 27(6):e26313. PubMed ID: 38926935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
    BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
    AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
    Inzaule SC; Hamers RL; Doherty M; Shafer RW; Bertagnolio S; Rinke de Wit TF
    Lancet Infect Dis; 2019 Jul; 19(7):e246-e252. PubMed ID: 30902440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz.
    Black V; Schwartz SR
    Lancet HIV; 2018 Dec; 5(12):e732-e736. PubMed ID: 30527330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The promise of paediatric dolutegravir.
    Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
    J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
    [No Abstract]   [Full Text] [Related]  

  • 40. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
    Zash R; Makhema J; Shapiro RL
    N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.